{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T00:27:19Z","timestamp":1792974439803,"version":"4.5.0"},"reference-count":146,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,2,10]],"date-time":"2015-02-10T00:00:00Z","timestamp":1423526400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Cardiol"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1038\/nrcardio.2015.5","type":"journal-article","created":{"date-parts":[[2015,2,10]],"date-time":"2015-02-10T11:44:30Z","timestamp":1423568670000},"page":"199-211","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":342,"title":["Anti-inflammatory therapies for atherosclerosis"],"prefix":"10.1038","volume":"12","author":[{"given":"Magnus","family":"B\u00e4ck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00f6ran K.","family":"Hansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,2,10]]},"reference":[{"key":"BFnrcardio20155_CR1","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1056\/NEJMra043430","volume":"352","author":"GK Hansson","year":"2005","unstructured":"Hansson, G. K. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 352, 1685\u20131695 (2005).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio20155_CR2","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nature10146","volume":"473","author":"P Libby","year":"2011","unstructured":"Libby, P., Ridker, P. M. & Hansson, G. K. Progress and challenges in translating the biology of atherosclerosis. Nature 473, 317\u2013325 (2011).","journal-title":"Nature"},{"key":"BFnrcardio20155_CR3","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1172\/JCI111934","volume":"76","author":"L Jonasson","year":"1985","unstructured":"Jonasson, L., Holm, J., Skalli, O., Gabbiani, G. & Hansson, G. K. Expression of class II transplantation antigen on vascular smooth muscle cells in human atherosclerosis. J. Clin. Invest. 76, 125\u2013131 (1985).","journal-title":"J. Clin. Invest."},{"key":"BFnrcardio20155_CR4","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1084\/jem.170.5.1595","volume":"170","author":"GK Hansson","year":"1989","unstructured":"Hansson, G. K., Hellstrand, M., Rymo, L., Rubbia, L. & Gabbiani, G. Interferon gamma inhibits both proliferation and expression of differentiation-specific alpha-smooth muscle actin in arterial smooth muscle cells. J. Exp. Med. 170, 1595\u20131608 (1989).","journal-title":"J. Exp. Med."},{"key":"BFnrcardio20155_CR5","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1161\/hc0902.104353","volume":"105","author":"P Libby","year":"2002","unstructured":"Libby, P., Ridker, P. M. & Maseri, A. Inflammation and atherosclerosis. Circulation 105, 1135\u20131143 (2002).","journal-title":"Circulation"},{"key":"BFnrcardio20155_CR6","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1073\/pnas.86.4.1372","volume":"86","author":"W Palinski","year":"1989","unstructured":"Palinski, W.  et al. Low density lipoprotein undergoes oxidative modification in vivo. Proc. Natl Acad. Sci. USA 86, 1372\u20131376 (1989).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrcardio20155_CR7","doi-asserted-by":"publisher","first-page":"3893","DOI":"10.1073\/pnas.92.9.3893","volume":"92","author":"S Stemme","year":"1995","unstructured":"Stemme, S.  et al. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc. Natl Acad. Sci. USA 92, 3893\u20133897 (1995).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrcardio20155_CR8","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/28204","volume":"394","author":"F Mach","year":"1998","unstructured":"Mach, F., Schonbeck, U., Sukhova, G. K., Atkinson, E. & Libby, P. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature 394, 200\u2013203 (1998).","journal-title":"Nature"},{"key":"BFnrcardio20155_CR9","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1172\/JCI119892","volume":"102","author":"A Nicoletti","year":"1998","unstructured":"Nicoletti, A., Kaveri, S., Caligiuri, G., Bariety, J. & Hansson, G. K. Immunoglobulin treatment reduces atherosclerosis in apo E knockout mice. J. Clin. Invest. 102, 910\u2013918 (1998).","journal-title":"J. Clin. Invest."},{"key":"BFnrcardio20155_CR10","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/ni.2001","volume":"12","author":"GK Hansson","year":"2011","unstructured":"Hansson, G. K. & Hermansson, A. The immune system in atherosclerosis. Nat. Immunol. 12, 204\u2013212 (2011).","journal-title":"Nat. Immunol."},{"key":"BFnrcardio20155_CR11","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1073\/pnas.85.7.2303","volume":"85","author":"L Jonasson","year":"1988","unstructured":"Jonasson, L., Holm, J. & Hansson, G. K. Cyclosporin A inhibits smooth muscle proliferation in the vascular response to injury. Proc. Natl Acad. Sci. USA 85, 2303\u20132306 (1988).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrcardio20155_CR12","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1056\/NEJMp038141","volume":"349","author":"AR Marks","year":"2003","unstructured":"Marks, A. R. Sirolimus for the prevention of in-stent restenosis in a coronary artery. N. Engl. J. Med. 349, 1307\u20131309 (2003).","journal-title":"N. Engl. J. Med."},{"key":"BFnrcardio20155_CR13","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1084\/jem.20091293","volume":"207","author":"E Lutgens","year":"2010","unstructured":"Lutgens, E.  et al. Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profile. J. Exp. Med. 207, 391\u2013404 (2010).","journal-title":"J. Exp. Med."},{"key":"BFnrcardio20155_CR14","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.1073\/pnas.1400419111","volume":"111","author":"A Chatzigeorgiou","year":"2014","unstructured":"Chatzigeorgiou, A.  et al. Blocking CD40-TRAF6 signaling is a therapeutic target in obesity-associated insulin resistance. Proc. Natl Acad. Sci. USA 111, 2686\u20132691 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrcardio20155_CR15","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1136\/ard.60.8.729","volume":"60","author":"M Cutolo","year":"2001","unstructured":"Cutolo, M., Sulli, A., Pizzorni, C., Seriolo, B. & Straub, R. H. Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis. Ann. Rheum. Dis. 60, 729\u2013735 (2001).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrcardio20155_CR16","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1097\/FJC.0b013e318241c385","volume":"59","author":"A Bulgarelli","year":"2012","unstructured":"Bulgarelli, A., Martins Dias, A. A., Caramelli, B. & Maranhao, R. C. Treatment with methotrexate inhibits atherogenesis in cholesterol-fed rabbits. J. Cardiovasc. Pharmacol. 59, 308\u2013314 (2012).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"BFnrcardio20155_CR17","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1093\/rheumatology\/kep366","volume":"49","author":"SL Westlake","year":"2010","unstructured":"Westlake, S. L.  et al. The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford) 49, 295\u2013307 (2010).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrcardio20155_CR18","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1016\/j.amjcard.2011.06.054","volume":"108","author":"R Micha","year":"2011","unstructured":"Micha, R.  et al. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am. J. Cardiol. 108, 1362\u20131370 (2011).","journal-title":"Am. J. Cardiol."},{"key":"BFnrcardio20155_CR19","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/j.1365-2796.2012.02593.x","volume":"273","author":"O Ahlehoff","year":"2013","unstructured":"Ahlehoff, O.  et al. Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: a Danish real-world cohort study. J. Intern. Med. 273, 197\u2013204 (2013).","journal-title":"J. Intern. Med."},{"key":"BFnrcardio20155_CR20","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ahj.2013.03.018","volume":"166","author":"BM Everett","year":"2013","unstructured":"Everett, B. M.  et al. Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. Am. Heart J. 166, 199\u2013207.e15 (2013).","journal-title":"Am. Heart J."},{"key":"BFnrcardio20155_CR21","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s11883-013-0391-z","volume":"16","author":"SM Nidorf","year":"2014","unstructured":"Nidorf, S. M., Eikelboom, J. W. & Thompson, P. L. Colchicine for secondary prevention of cardiovascular disease. Curr. Atheroscler. Rep. 16, 391 (2014).","journal-title":"Curr. Atheroscler. Rep."},{"key":"BFnrcardio20155_CR22","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1007\/s11926-008-0036-3","volume":"10","author":"G Nuki","year":"2008","unstructured":"Nuki, G. Colchicine: its mechanism of action and efficacy in crystal-induced inflammation. Curr. Rheumatol. Rep. 10, 218\u2013227 (2008).","journal-title":"Curr. Rheumatol. Rep."},{"key":"BFnrcardio20155_CR23","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nature04516","volume":"440","author":"F Martinon","year":"2006","unstructured":"Martinon, F., Petrilli, V., Mayor, A., Tardivel, A. & Tschopp, J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440, 237\u2013241 (2006).","journal-title":"Nature"},{"key":"BFnrcardio20155_CR24","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1038\/nature08938","volume":"464","author":"P Duewell","year":"2010","unstructured":"Duewell, P.  et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464, 1357\u20131361 (2010).","journal-title":"Nature"},{"key":"BFnrcardio20155_CR25","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.3899\/jrheum.111533","volume":"39","author":"DB Crittenden","year":"2012","unstructured":"Crittenden, D. B.  et al. Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout. J. Rheumatol. 39, 1458\u20131464 (2012).","journal-title":"J. Rheumatol."},{"key":"BFnrcardio20155_CR26","doi-asserted-by":"publisher","unstructured":"Grimaldi-Bensouda, L.  et al. Impact of allopurinol on risk of myocardial infarction. Ann. Rheum. Dis. \n                    http:\/\/dx.doi.org\/10.1136\/annrheumdis-2012-202972\n                    \n                  .","DOI":"10.1136\/annrheumdis-2012-202972"},{"key":"BFnrcardio20155_CR27","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.jacc.2012.10.027","volume":"61","author":"SM Nidorf","year":"2013","unstructured":"Nidorf, S. M., Eikelboom, J. W., Budgeon, C. A. & Thompson, P. L. Low-dose colchicine for secondary prevention of cardiovascular disease. J. Am. Coll. Cardiol. 61, 404\u2013410 (2013).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrcardio20155_CR28","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.ahj.2011.06.012","volume":"162","author":"PM Ridker","year":"2011","unstructured":"Ridker, P. M., Thuren, T., Zalewski, A. & Libby, P. Interleukin-1\u03b2 inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am. Heart J. 162, 597\u2013605 (2011).","journal-title":"Am. Heart J."},{"key":"BFnrcardio20155_CR29","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.atherosclerosis.2010.08.077","volume":"213","author":"EB Kaya","year":"2010","unstructured":"Kaya, E. B.  et al. Serum uric acid levels predict the severity and morphology of coronary atherosclerosis detected by multidetector computed tomography. Atherosclerosis 213, 178\u2013183 (2010).","journal-title":"Atherosclerosis"},{"key":"BFnrcardio20155_CR30","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1111\/j.1755-5922.2011.00277.x","volume":"30","author":"P Higgins","year":"2012","unstructured":"Higgins, P.  et al. Xanthine oxidase inhibition for the treatment of cardiovascular disease: a systematic review and meta-analysis. Cardiovasc. Ther. 30, 217\u2013226 (2012).","journal-title":"Cardiovasc. Ther."},{"key":"BFnrcardio20155_CR31","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1161\/CIRCULATIONAHA.106.651117","volume":"114","author":"J George","year":"2006","unstructured":"George, J., Carr, E., Davies, J., Belch, J. J. & Struthers, A. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation 114, 2508\u20132516 (2006).","journal-title":"Circulation"},{"key":"BFnrcardio20155_CR32","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1161\/ATVBAHA.111.234559","volume":"32","author":"A Kushiyama","year":"2012","unstructured":"Kushiyama, A.  et al. Xanthine oxidoreductase is involved in macrophage foam cell formation and atherosclerosis development. Arterioscler. Thromb. Vasc. Biol. 32, 291\u2013298 (2012).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"BFnrcardio20155_CR33","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1016\/S0140-6736(10)60391-1","volume":"375","author":"A Noman","year":"2010","unstructured":"Noman, A., Ang, D. S., Ogston, S., Lang, C. C. & Struthers, A. D. Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. Lancet 375, 2161\u20132167 (2010).","journal-title":"Lancet"},{"key":"BFnrcardio20155_CR34","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.ijcard.2009.08.037","volume":"145","author":"E Rentoukas","year":"2010","unstructured":"Rentoukas, E.  et al. The prognostic impact of allopurinol in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Int. J. Cardiol. 145, 257\u2013258 (2010).","journal-title":"Int. J. Cardiol."},{"key":"BFnrcardio20155_CR35","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/S0140-6736(94)90007-8","volume":"343","author":"EJ Topol","year":"1994","unstructured":"Topol, E. J.  et al. Randomised trial of coronary intervention with antibody against platelet IIb\/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators. Lancet 343, 881\u2013886 (1994).","journal-title":"Lancet"},{"key":"BFnrcardio20155_CR36","first-page":"445","volume":"24","author":"S Wallberg-Jonsson","year":"1997","unstructured":"Wallberg-Jonsson, S., Ohman, M. L. & Dahlqvist, S. R. Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. J. Rheumatol. 24, 445\u2013451 (1997).","journal-title":"J. Rheumatol."},{"key":"BFnrcardio20155_CR37","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.1002\/art.24855","volume":"60","author":"ME Holmqvist","year":"2009","unstructured":"Holmqvist, M. E.  et al. No increased occurrence of ischemic heart disease prior to the onset of rheumatoid arthritis: results from two Swedish population-based rheumatoid arthritis cohorts. Arthritis Rheum. 60, 2861\u20132869 (2009).","journal-title":"Arthritis Rheum."},{"key":"BFnrcardio20155_CR38","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/nrrheum.2009.181","volume":"5","author":"PC Taylor","year":"2009","unstructured":"Taylor, P. C. & Feldmann, M. Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nat. Rev. Rheumatol. 5, 578\u2013582 (2009).","journal-title":"Nat. Rev. Rheumatol."},{"key":"BFnrcardio20155_CR39","first-page":"1213","volume":"32","author":"LT Jacobsson","year":"2005","unstructured":"Jacobsson, L. T.  et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J. Rheumatol. 32, 1213\u20131218 (2005).","journal-title":"J. Rheumatol."},{"key":"BFnrcardio20155_CR40","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1002\/art.22809","volume":"56","author":"WG Dixon","year":"2007","unstructured":"Dixon, W. G.  et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor \u03b1 therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 56, 2905\u20132912 (2007).","journal-title":"Arthritis Rheum."},{"key":"BFnrcardio20155_CR41","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1084\/jem.160.2.618","volume":"160","author":"MP Bevilacqua","year":"1984","unstructured":"Bevilacqua, M. P., Pober, J. S., Majeau, G. R., Cotran, R. S. & Gimbrone, M. A. Jr. Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J. Exp. Med. 160, 618\u2013623 (1984).","journal-title":"J. Exp. Med."},{"key":"BFnrcardio20155_CR42","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1172\/JCI113346","volume":"81","author":"P Libby","year":"1988","unstructured":"Libby, P., Warner, S. J. & Friedman, G. B. Interleukin 1: a mitogen for human vascular smooth muscle cells that induces the release of growth-inhibitory prostanoids. J. Clin. Invest. 81, 487\u201398 (1988).","journal-title":"J. Clin. Invest."},{"key":"BFnrcardio20155_CR43","doi-asserted-by":"publisher","first-page":"e11765","DOI":"10.1371\/journal.pone.0011765","volume":"5","author":"K Rajamaki","year":"2010","unstructured":"Rajamaki, K.  et al. Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. PLoS ONE 5, e11765 (2010).","journal-title":"PLoS ONE"},{"key":"BFnrcardio20155_CR44","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1161\/CIRCULATIONAHA.112.122556","volume":"126","author":"PM Ridker","year":"2012","unstructured":"Ridker, P. M.  et al. Effects of interleukin-1\u03b2 inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation 126, 2739\u20132748 (2012).","journal-title":"Circulation"},{"key":"BFnrcardio20155_CR45","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1161\/01.ATV.19.3.734","volume":"19","author":"TS Lee","year":"1999","unstructured":"Lee, T. S., Yen, H. C., Pan, C. C. & Chau, L. Y. The role of interleukin 12 in the development of atherosclerosis in ApoE-deficient mice. Arterioscler. Thromb. Vasc. Biol. 19, 734\u2013742 (1999).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"BFnrcardio20155_CR46","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/S0002-9440(10)63471-2","volume":"163","author":"P Davenport","year":"2003","unstructured":"Davenport, P. & Tipping, P. G. The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice. Am. J. Pathol. 163, 1117\u20131125 (2003).","journal-title":"Am. J. Pathol."},{"key":"BFnrcardio20155_CR47","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1093\/ajh\/hps032","volume":"26","author":"K Yong","year":"2013","unstructured":"Yong, K.  et al. Interleukin-12 is associated with arterial stiffness in healthy individuals. Am. J. Hypertens. 26, 159\u2013162 (2013).","journal-title":"Am. J. Hypertens."},{"key":"BFnrcardio20155_CR48","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.clinbiochem.2011.12.010","volume":"45","author":"A David","year":"2012","unstructured":"David, A.  et al. Interleukin-23 serum levels in patients affected by peripheral arterial disease. Clin. Biochem. 45, 275\u2013258 (2012).","journal-title":"Clin. Biochem."},{"key":"BFnrcardio20155_CR49","doi-asserted-by":"publisher","first-page":"196ra100","DOI":"10.1126\/scitranslmed.3006133","volume":"5","author":"A Gistera","year":"2013","unstructured":"Gistera, A.  et al. Transforming growth factor-\u03b2 signaling in T cells promotes stabilization of atherosclerotic plaques through an interleukin-17-dependent pathway. Sci. Transl. Med. 5, 196ra100 (2013).","journal-title":"Sci. Transl. Med."},{"key":"BFnrcardio20155_CR50","first-page":"864","volume":"306","author":"C Ryan","year":"2011","unstructured":"Ryan, C.  et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA 306, 864\u2013871 (2011).","journal-title":"JAMA"},{"key":"BFnrcardio20155_CR51","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1111\/j.1468-3083.2012.04500.x","volume":"27","author":"T Tzellos","year":"2013","unstructured":"Tzellos, T., Kyrgidis, A. & Zouboulis, C. C. Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12\/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials. J. Eur. Acad. Dermatol. Venereol. 27, 622\u2013627 (2013).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"BFnrcardio20155_CR52","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1002\/emmm.201100183","volume":"3","author":"RR Koenen","year":"2011","unstructured":"Koenen, R. R. & Weber, C. Chemokines: established and novel targets in atherosclerosis. EMBO Mol. Med. 3, 713\u2013725 (2011).","journal-title":"EMBO Mol. Med."},{"key":"BFnrcardio20155_CR53","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1038\/29788","volume":"394","author":"L Boring","year":"1998","unstructured":"Boring, L., Gosling, J., Cleary, M. & Charo, I. F. Decreased lesion formation in CCR2\u2212\/\u2212 mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 394, 894\u2013897 (1998).","journal-title":"Nature"},{"key":"BFnrcardio20155_CR54","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.amjcard.2010.11.005","volume":"107","author":"J Gilbert","year":"2011","unstructured":"Gilbert, J.  et al. Effect of CC chemokine receptor 2 CCR2 blockade on serum C-reactive protein in individuals at atherosclerotic risk and with a single nucleotide polymorphism of the monocyte chemoattractant protein-1 promoter region. Am. J. Cardiol. 107, 906\u2013911 (2011).","journal-title":"Am. J. Cardiol."},{"key":"BFnrcardio20155_CR55","doi-asserted-by":"publisher","first-page":"2898","DOI":"10.1172\/JCI44925","volume":"121","author":"C Weber","year":"2011","unstructured":"Weber, C.  et al. CCL17-expressing dendritic cells drive atherosclerosis by restraining regulatory T cell homeostasis in mice. J. Clin. Invest. 121, 2898\u20132910 (2011).","journal-title":"J. Clin. Invest."},{"issue":"Suppl.","key":"BFnrcardio20155_CR56","doi-asserted-by":"publisher","first-page":"S237","DOI":"10.1194\/jlr.R800033-JLR200","volume":"50","author":"JE Burke","year":"2009","unstructured":"Burke, J. E. & Dennis, E. A. Phospholipase A2 structure\/function, mechanism, and signaling. J. Lipid. Res. 50 (Suppl.), S237\u2013S242 (2009).","journal-title":"J. Lipid. Res."},{"key":"BFnrcardio20155_CR57","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s11886-009-0064-2","volume":"11","author":"RS Rosenson","year":"2009","unstructured":"Rosenson, R. S. & Gelb, M. H. Secretory phospholipase A2: a multifaceted family of proatherogenic enzymes. Curr. Cardiol. Rep. 11, 445\u2013451 (2009).","journal-title":"Curr. Cardiol. Rep."},{"key":"BFnrcardio20155_CR58","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1517\/13543780903184583","volume":"18","author":"KE Suckling","year":"2009","unstructured":"Suckling, K. E. Phospholipase A2 inhibitors in the treatment of atherosclerosis: a new approach moves forward in the clinic. Expert Opin. Investig. Drugs 18, 1425\u20131430 (2009).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"BFnrcardio20155_CR59","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1093\/eurheartj\/ehs148","volume":"33","author":"RS Rosenson","year":"2012","unstructured":"Rosenson, R. S. & Hurt-Camejo, E. Phospholipase A2 enzymes and the risk of atherosclerosis. Eur. Heart J. 33, 2899\u20132909 (2012).","journal-title":"Eur. Heart J."},{"key":"BFnrcardio20155_CR60","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1097\/FJC.0b013e318195bfbc","volume":"53","author":"H Fraser","year":"2009","unstructured":"Fraser, H.  et al. Varespladib (A-002), a secretory phospholipase A2 inhibitor, reduces atherosclerosis and aneurysm formation in ApoE\u2212\/\u2212 mice. J. Cardiovasc. Pharmacol. 53, 60\u201365 (2009).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"BFnrcardio20155_CR61","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1194\/jlr.M800361-JLR200","volume":"50","author":"Z Shaposhnik","year":"2009","unstructured":"Shaposhnik, Z., Wang, X., Trias, J., Fraser, H. & Lusis, A. J. The synergistic inhibition of atherogenesis in apoE\u2212\/\u2212 mice between pravastatin and the sPLA2 inhibitor varespladib (A-002). J. Lipid Res. 50, 623\u2013629 (2009).","journal-title":"J. Lipid Res."},{"key":"BFnrcardio20155_CR62","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.jacc.2010.06.015","volume":"56","author":"RS Rosenson","year":"2010","unstructured":"Rosenson, R. S.  et al. Effects of varespladib methyl on biomarkers and major cardiovascular events in acute coronary syndrome patients. J. Am. Coll. Cardiol. 56, 1079\u20131088 (2010).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrcardio20155_CR63","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1001\/jama.2013.282836","volume":"311","author":"SJ Nicholls","year":"2014","unstructured":"Nicholls, S. J.  et al. Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial. JAMA 311, 252\u2013262 (2014).","journal-title":"JAMA"},{"key":"BFnrcardio20155_CR64","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1161\/ATVBAHA.112.300309","volume":"33","author":"H Ait-Oufella","year":"2013","unstructured":"Ait-Oufella, H.  et al. Group X secreted phospholipase A2 limits the development of atherosclerosis in LDL receptor-null mice. Arterioscler. Thromb. Vasc. Biol. 33, 466\u2013473 (2013).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"BFnrcardio20155_CR65","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1161\/01.ATV.0000280571.28102.d4","volume":"27","author":"S Tsimikas","year":"2007","unstructured":"Tsimikas, S., Tsironis, L. D. & Tselepis, A. D. New insights into the role of lipoprotein(a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 27, 2094\u20132099 (2007).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"BFnrcardio20155_CR66","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1161\/01.ATV.0000244681.72738.bc","volume":"26","author":"FD Kolodgie","year":"2006","unstructured":"Kolodgie, F. D.  et al. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 26, 2523\u20132529 (2006).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"BFnrcardio20155_CR67","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1038\/nm.1870","volume":"14","author":"RL Wilensky","year":"2008","unstructured":"Wilensky, R. L.  et al. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat. Med. 14, 1059\u20131066 (2008).","journal-title":"Nat. Med."},{"key":"BFnrcardio20155_CR68","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1161\/CIRCULATIONAHA.108.771899","volume":"118","author":"PW Serruys","year":"2008","unstructured":"Serruys, P. W.  et al. Effects of the direct lipoprotein-associated phospholipase A2 inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 118, 1172\u20131182 (2008).","journal-title":"Circulation"},{"key":"BFnrcardio20155_CR69","doi-asserted-by":"crossref","unstructured":"STABILITY Investigators. Darapladib for preventing ischemic events in stable coronary heart disease. N. Engl. J. Med. 370, 1702\u20131711 (2014).","DOI":"10.1056\/NEJMoa1315878"},{"key":"BFnrcardio20155_CR70","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1001\/jama.2014.11061","volume":"312","author":"ML O'Donoghue","year":"2014","unstructured":"O'Donoghue, M. L.  et al. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID\u2013TIMI 52 randomized clinical trial. JAMA 312, 1006\u20131015 (2014).","journal-title":"JAMA"},{"key":"BFnrcardio20155_CR71","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/jth.12472","volume":"12","author":"V Capra","year":"2014","unstructured":"Capra, V., B\u00e4ck, M., Angiolillo, D. J., Cattaneo, M. & Sakariassen, K. S. Impact of vascular thromboxane prostanoid receptor activation on hemostasis, thrombosis, oxidative stress, and inflammation. J. Thromb. Haemost. 12, 126\u2013137 (2014).","journal-title":"J. Thromb. Haemost."},{"key":"BFnrcardio20155_CR72","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s00109-010-0621-6","volume":"88","author":"A Gabrielsen","year":"2010","unstructured":"Gabrielsen, A.  et al. Thromboxane synthase expression and thromboxane A2 production in the atherosclerotic lesion. J. Mol. Med. (Berl.) 88, 795\u2013806 (2010).","journal-title":"J. Mol. Med. (Berl.)"},{"key":"BFnrcardio20155_CR73","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.bbrc.2013.10.078","volume":"441","author":"MH Petri","year":"2013","unstructured":"Petri, M. H.  et al. Effects of the dual TP receptor antagonist and thromboxane synthase inhibitor EV-077 on human endothelial and vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 441, 393\u2013398 (2013).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"BFnrcardio20155_CR74","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1016\/S0140-6736(11)60600-4","volume":"377","author":"MG Bousser","year":"2011","unstructured":"Bousser, M. G.  et al. Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial. Lancet 377, 2013\u20132022 (2011).","journal-title":"Lancet"},{"key":"BFnrcardio20155_CR75","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1053\/ejvs.2000.1145","volume":"20","author":"V Stemme","year":"2000","unstructured":"Stemme, V., Swedenborg, J., Claesson, H. & Hansson, G. K. Expression of cyclo-oxygenase-2 in human atherosclerotic carotid arteries. Eur. J. Vasc. Endovasc. Surg. 20, 146\u2013152 (2000).","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"key":"BFnrcardio20155_CR76","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1093\/eurheartj\/ehr421","volume":"33","author":"M B\u00e4ck","year":"2012","unstructured":"B\u00e4ck, M., Yin, L. & Ingelsson, E. Cyclooxygenase-2 inhibitors and cardiovascular risk in a nation-wide cohort study after the withdrawal of rofecoxib. Eur. Heart J. 33, 1928\u20131933 (2012).","journal-title":"Eur. Heart J."},{"key":"BFnrcardio20155_CR77","doi-asserted-by":"publisher","first-page":"H1882","DOI":"10.1152\/ajpheart.00092.2009","volume":"297","author":"N Foudi","year":"2009","unstructured":"Foudi, N.  et al. Altered reactivity to norepinephrine through COX-2 induction by vascular injury in hypercholesterolemic rabbits. Am. J. Physiol. Heart Circ. Physiol. 297, H1882\u2013H1888 (2009).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"BFnrcardio20155_CR78","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1161\/CIRCULATIONAHA.109.910687","volume":"121","author":"Y Hui","year":"2010","unstructured":"Hui, Y.  et al. Targeted deletions of cyclooxygenase-2 and atherogenesis in mice. Circulation 121, 2654\u20132660 (2010).","journal-title":"Circulation"},{"key":"BFnrcardio20155_CR79","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1161\/CIRCULATIONAHA.113.007913","volume":"129","author":"SY Tang","year":"2014","unstructured":"Tang, S. Y.  et al. Cyclooxygenase-2 in endothelial and vascular smooth muscle cells restrains atherogenesis in hyperlipidemic mice. Circulation 129, 1761\u20131769 (2014).","journal-title":"Circulation"},{"key":"BFnrcardio20155_CR80","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1161\/CIRCULATIONAHA.105.591537","volume":"113","author":"VR Babaev","year":"2006","unstructured":"Babaev, V. R.  et al. Cyclooxygenase-1 deficiency in bone marrow cells increases early atherosclerosis in apolipoprotein E- and low-density lipoprotein receptor-null mice. Circulation 113, 108\u2013117 (2006).","journal-title":"Circulation"},{"key":"BFnrcardio20155_CR81","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.bbrc.2010.02.173","volume":"396","author":"O R\u00e5dmark","year":"2010","unstructured":"R\u00e5dmark, O. & Samuelsson, B. Regulation of the activity of 5-lipoxygenase, a key enzyme in leukotriene biosynthesis. Biochem. Biophys. Res. Commun. 396, 105\u2013110 (2010).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"BFnrcardio20155_CR82","doi-asserted-by":"publisher","first-page":"3551","DOI":"10.1111\/bph.12665","volume":"171","author":"M B\u00e4ck","year":"2014","unstructured":"B\u00e4ck, M.  et al. Update on leukotriene, lipoxin and oxoeicosanoid receptors: IUPHAR Review 7. Br. J. Pharmacol. 171, 3551\u20133574 (2014).","journal-title":"Br. J. Pharmacol."},{"key":"BFnrcardio20155_CR83","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1080\/07853890600982737","volume":"38","author":"M B\u00e4ck","year":"2006","unstructured":"B\u00e4ck, M. & Hansson, G. K. Leukotriene receptors in atherosclerosis. Ann. Med. 38, 493\u2013502 (2006).","journal-title":"Ann. Med."},{"key":"BFnrcardio20155_CR84","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1161\/CIRCULATIONAHA.110.966846","volume":"123","author":"E Nagy","year":"2011","unstructured":"Nagy, E.  et al. Upregulation of the 5-lipoxygenase pathway in human aortic valves correlates with severity of stenosis and leads to leukotriene-induced effects on valvular myofibroblasts. Circulation 123, 1316\u20131325 (2011).","journal-title":"Circulation"},{"key":"BFnrcardio20155_CR85","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1093\/cvr\/cvt040","volume":"99","author":"M B\u00e4ck","year":"2013","unstructured":"B\u00e4ck, M., Gasser, T. C., Michel, J. B. & Caligiuri, G. Biomechanical factors in the biology of aortic wall and aortic valve diseases. Cardiovasc. Res. 99, 232\u2013241 (2013).","journal-title":"Cardiovasc. Res."},{"key":"BFnrcardio20155_CR86","doi-asserted-by":"publisher","first-page":"3013","DOI":"10.1093\/eurheartj\/ehu353","volume":"14","author":"BR Kwak","year":"2014","unstructured":"Kwak, B. R.  et al. Biomechanical factors in atherosclerosis: mechanisms and clinical implications. Eur. Heart J. 14, 3013\u20133020 (2014).","journal-title":"Eur. Heart J."},{"key":"BFnrcardio20155_CR87","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1161\/ATVBAHA.113.302642","volume":"34","author":"F Otsuka","year":"2014","unstructured":"Otsuka, F., Sakakura, K., Yahagi, K., Joner, M. & Virmani, R. Has our understanding of calcification in human coronary atherosclerosis progressed? Arterioscler. Thromb. Vasc. Biol. 34, 724\u2013736 (2014).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"BFnrcardio20155_CR88","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1073\/pnas.242716099","volume":"100","author":"R Spanbroek","year":"2003","unstructured":"Spanbroek, R.  et al. Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc. Natl Acad. Sci. USA 100, 1238\u20131243 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrcardio20155_CR89","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1161\/01.CIR.97.24.2406","volume":"97","author":"S Allen","year":"1998","unstructured":"Allen, S., Dashwood, M., Morrison, K. & Yacoub, M. Differential leukotriene constrictor responses in human atherosclerotic coronary arteries. Circulation 97, 2406\u20132413 (1998).","journal-title":"Circulation"},{"key":"BFnrcardio20155_CR90","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1111\/j.1365-2362.2010.02261.x","volume":"40","author":"R De Caterina","year":"2010","unstructured":"De Caterina, R.  et al. Sulfido-peptide leukotrienes in coronary heart disease\u2014relationship with disease instability and myocardial ischaemia. Eur. J. Clin. Invest. 40, 258\u2013272 (2010).","journal-title":"Eur. J. Clin. Invest."},{"key":"BFnrcardio20155_CR91","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1097\/HJH.0b013e328363dccc","volume":"31","author":"C Labat","year":"2013","unstructured":"Labat, C.  et al. Inflammatory mediators in saliva associated with arterial stiffness and subclinical atherosclerosis. J. Hypertens. 31, 2251\u20132258 (2013).","journal-title":"J. Hypertens."},{"key":"BFnrcardio20155_CR92","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1194\/jlr.P022814","volume":"53","author":"F Stanke-Labesque","year":"2012","unstructured":"Stanke-Labesque, F.  et al. Leukotriene B4 pathway activation and atherosclerosis in obstructive sleep apnea. J. Lipid Res. 53, 1944\u20131951 (2012).","journal-title":"J. Lipid Res."},{"key":"BFnrcardio20155_CR93","doi-asserted-by":"publisher","first-page":"3116","DOI":"10.2174\/138161209789058020","volume":"15","author":"M B\u00e4ck","year":"2009","unstructured":"B\u00e4ck, M. Inhibitors of the 5-lipoxygenase pathway in atherosclerosis. Curr. Pharm. Des. 15, 3116\u20133132 (2009).","journal-title":"Curr. Pharm. Des."},{"key":"BFnrcardio20155_CR94","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/j.1365-2362.2006.01606.x","volume":"36","author":"J Jawien","year":"2006","unstructured":"Jawien, J.  et al. Inhibition of five lipoxygenase activating protein (FLAP) by MK-886 decreases atherosclerosis in apoE\/LDLR-double knockout mice. Eur. J. Clin. Invest. 36, 141\u2013146 (2006).","journal-title":"Eur. J. Clin. Invest."},{"key":"BFnrcardio20155_CR95","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1161\/01.RES.0000264498.60702.0d","volume":"100","author":"M B\u00e4ck","year":"2007","unstructured":"B\u00e4ck, M., Sultan, A., Ovchinnikova, O. & Hansson, G. K. 5-Lipoxygenase-activating protein: a potential link between innate and adaptive immunity in atherosclerosis and adipose tissue inflammation. Circ. Res. 100, 946\u2013949 (2007).","journal-title":"Circ. Res."},{"key":"BFnrcardio20155_CR96","doi-asserted-by":"publisher","first-page":"6727","DOI":"10.1073\/pnas.1115313109","volume":"109","author":"Z Yu","year":"2012","unstructured":"Yu, Z.  et al. Disruption of the 5-lipoxygenase pathway attenuates atherogenesis consequent to COX-2 deletion in mice. Proc. Natl Acad. Sci. USA 109, 6727\u20136732 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrcardio20155_CR97","doi-asserted-by":"publisher","first-page":"17501","DOI":"10.1073\/pnas.0505845102","volume":"102","author":"M B\u00e4ck","year":"2005","unstructured":"B\u00e4ck, M.  et al. Leukotriene B4 signaling through NF-\u03baB-dependent BLT1 receptors on vascular smooth muscle cells in atherosclerosis and intimal hyperplasia. Proc. Natl Acad. Sci. USA 102, 17501\u201317506 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrcardio20155_CR98","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1161\/CIRCULATIONAHA.105.545616","volume":"112","author":"EA Heller","year":"2005","unstructured":"Heller, E. A.  et al. Inhibition of atherogenesis in BLT1-deficient mice reveals a role for LTB4 and BLT1 in smooth muscle cell recruitment. Circulation 112, 578\u2013586 (2005).","journal-title":"Circulation"},{"key":"BFnrcardio20155_CR99","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1161\/ATVBAHA.108.181750","volume":"29","author":"H Hlawaty","year":"2009","unstructured":"Hlawaty, H.  et al. Leukotriene receptor antagonism and the prevention of extracellular matrix degradation during atherosclerosis and in-stent stenosis. Arterioscler. Thromb. Vasc. Biol. 29, 518\u2013524 (2009).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"BFnrcardio20155_CR100","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1161\/CIRCULATIONAHA.107.747667","volume":"117","author":"CF Mueller","year":"2008","unstructured":"Mueller, C. F.  et al. Multidrug resistance protein-1 affects oxidative stress, endothelial dysfunction, and atherogenesis via leukotriene C4 export. Circulation 117, 2912\u20132918 (2008).","journal-title":"Circulation"},{"key":"BFnrcardio20155_CR101","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1378\/chest.07-0831","volume":"132","author":"H Allayee","year":"2007","unstructured":"Allayee, H.  et al. The effect of montelukast and low-dose theophylline on cardiovascular disease risk factors in asthmatics. Chest 132, 868\u2013874 (2007).","journal-title":"Chest"},{"key":"BFnrcardio20155_CR102","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.jaci.2011.11.052","volume":"129","author":"E Ingelsson","year":"2012","unstructured":"Ingelsson, E., Yin, L. & B\u00e4ck, M. Nationwide cohort study of the leukotriene receptor antagonist montelukast and incident or recurrent cardiovascular disease. J. Allergy Clin. Immunol. 129, 702\u2013707 e2 (2012).","journal-title":"J. Allergy Clin. Immunol."},{"key":"BFnrcardio20155_CR103","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1001\/jama.293.18.2245","volume":"293","author":"H Hakonarson","year":"2005","unstructured":"Hakonarson, H.  et al. Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial. JAMA 293, 2245\u20132256 (2005).","journal-title":"JAMA"},{"key":"BFnrcardio20155_CR104","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1161\/CIRCIMAGING.110.937169","volume":"3","author":"JC Tardif","year":"2010","unstructured":"Tardif, J. C.  et al. Treatment with 5-lipoxygenase inhibitor VIA-2291 (Atreleuton) in patients with recent acute coronary syndrome. Circ. Cardiovasc. Imaging 3, 298\u2013307 (2010).","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"BFnrcardio20155_CR105","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1161\/ATVBAHA.113.301715","volume":"33","author":"HQ Liu","year":"2013","unstructured":"Liu, H. Q.  et al. NOD2-mediated innate immune signaling regulates the eicosanoids in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 33, 2193\u20132201 (2013).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"BFnrcardio20155_CR106","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.jvs.2010.05.116","volume":"52","author":"A Bitto","year":"2010","unstructured":"Bitto, A.  et al. Evidence for markers of hypoxia and apoptosis in explanted human carotid atherosclerotic plaques. J. Vasc. Surg. 52, 1015\u20131021 (2010).","journal-title":"J. Vasc. Surg."},{"key":"BFnrcardio20155_CR107","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s00395-009-0072-9","volume":"105","author":"FH Seeger","year":"2010","unstructured":"Seeger, F. H.  et al. Inhibition of the p38 MAP kinase in vivo improves number and functional activity of vasculogenic cells and reduces atherosclerotic disease progression. Basic Res. Cardiol. 105, 389\u2013397 (2010).","journal-title":"Basic Res. Cardiol."},{"key":"BFnrcardio20155_CR108","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1161\/ATVBAHA.107.151175","volume":"28","author":"JB Morris","year":"2008","unstructured":"Morris, J. B.  et al. p38 MAPK inhibition reduces aortic ultrasmall superparamagnetic iron oxide uptake in a mouse model of atherosclerosis: MRI assessment. Arterioscler. Thromb. Vasc. Biol. 28, 265\u2013271 (2008).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"BFnrcardio20155_CR109","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s40256-014-0063-6","volume":"14","author":"M Fisk","year":"2014","unstructured":"Fisk, M., Gajendragadkar, P. R., Maki-Petaja, K. M., Wilkinson, I. B. & Cheriyan, J. Therapeutic potential of p38 MAP kinase inhibition in the management of cardiovascular disease. Am. J. Cardiovasc. Drugs 14, 155\u2013165 (2014).","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"BFnrcardio20155_CR110","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1161\/ATVBAHA.110.209205","volume":"30","author":"L Sarov-Blat","year":"2010","unstructured":"Sarov-Blat, L.  et al. Inhibition of p38 mitogen-activated protein kinase reduces inflammation after coronary vascular injury in humans. Arterioscler. Thromb. Vasc. Biol. 30, 2256\u20132263 (2010).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"BFnrcardio20155_CR111","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1161\/ATVBAHA.110.213793","volume":"30","author":"P Natarajan","year":"2010","unstructured":"Natarajan, P. & Cannon, C. P. Could direct inhibition of inflammation be the \u201cnext big thing\u201d in treating atherosclerosis? Arterioscler. Thromb. Vasc. Biol. 30, 2081\u20132083 (2010).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"BFnrcardio20155_CR112","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1161\/CIRCULATIONAHA.110.971986","volume":"123","author":"J Cheriyan","year":"2011","unstructured":"Cheriyan, J.  et al. Inhibition of p38 mitogen-activated protein kinase improves nitric oxide-mediated vasodilatation and reduces inflammation in hypercholesterolemia. Circulation 123, 515\u2013523 (2011).","journal-title":"Circulation"},{"key":"BFnrcardio20155_CR113","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.jcmg.2012.02.016","volume":"5","author":"M Elkhawad","year":"2012","unstructured":"Elkhawad, M.  et al. Effects of p38 mitogen-activated protein kinase inhibition on vascular and systemic inflammation in patients with atherosclerosis. JACC Cardiovasc. Imaging 5, 911\u2013922 (2012).","journal-title":"JACC Cardiovasc. Imaging"},{"key":"BFnrcardio20155_CR114","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.ahj.2012.07.030","volume":"164","author":"C Melloni","year":"2012","unstructured":"Melloni, C.  et al. The study of LoSmapimod treatment on inflammation and InfarCtSizE (SOLSTICE): design and rationale. Am. Heart J. 164, 646\u2013653.e3 (2012).","journal-title":"Am. Heart J."},{"key":"BFnrcardio20155_CR115","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/S0140-6736(14)60417-7","volume":"384","author":"LK Newby","year":"2014","unstructured":"Newby, L. K.  et al. Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial. Lancet 384, 1187\u20131195 (2014).","journal-title":"Lancet"},{"key":"BFnrcardio20155_CR116","doi-asserted-by":"publisher","first-page":"26714","DOI":"10.1074\/jbc.C500144200","volume":"280","author":"KM Parmar","year":"2005","unstructured":"Parmar, K. M.  et al. Statins exert endothelial atheroprotective effects via the KLF2 transcription factor. J. Biol. Chem. 280, 26714\u201326719 (2005).","journal-title":"J. Biol. Chem."},{"key":"BFnrcardio20155_CR117","doi-asserted-by":"publisher","first-page":"18882","DOI":"10.1074\/jbc.M109.009886","volume":"284","author":"F Ali","year":"2009","unstructured":"Ali, F.  et al. Induction of the cytoprotective enzyme heme oxygenase-1 by statins is enhanced in vascular endothelium exposed to laminar shear stress and impaired by disturbed flow. J. Biol. Chem. 284, 18882\u201318892 (2009).","journal-title":"J. Biol. Chem."},{"key":"BFnrcardio20155_CR118","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.cardiores.2006.07.008","volume":"72","author":"JV van Thienen","year":"2006","unstructured":"van Thienen, J. V.  et al. Shear stress sustains atheroprotective endothelial KLF2 expression more potently than statins through mRNA stabilization. Cardiovasc. Res. 72, 231\u2013240 (2006).","journal-title":"Cardiovasc. Res."},{"key":"BFnrcardio20155_CR119","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1161\/01.CIR.0000012917.74432.66","volume":"105","author":"D Sorescu","year":"2002","unstructured":"Sorescu, D.  et al. Superoxide production and expression of Nox family proteins in human atherosclerosis. Circulation 105, 1429\u20131435 (2002).","journal-title":"Circulation"},{"key":"BFnrcardio20155_CR120","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1161\/01.CIR.0000012748.58444.08","volume":"105","author":"TJ Guzik","year":"2002","unstructured":"Guzik, T. J.  et al. Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation 105, 1656\u20131662 (2002).","journal-title":"Circulation"},{"key":"BFnrcardio20155_CR121","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.atherosclerosis.2011.02.028","volume":"216","author":"AL Sheehan","year":"2011","unstructured":"Sheehan, A. L.  et al. Role for Nox1 NADPH oxidase in atherosclerosis. Atherosclerosis 216, 321\u2013326 (2011).","journal-title":"Atherosclerosis"},{"key":"BFnrcardio20155_CR122","doi-asserted-by":"publisher","first-page":"H24","DOI":"10.1152\/ajpheart.00799.2009","volume":"298","author":"CP Judkins","year":"2010","unstructured":"Judkins, C. P.  et al. Direct evidence of a role for Nox2 in superoxide production, reduced nitric oxide bioavailability, and early atherosclerotic plaque formation in ApoE\u2212\/\u2212 mice. Am. J. Physiol. Heart Circ. Physiol. 298, H24\u2013H32 (2010).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"BFnrcardio20155_CR123","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1161\/CIRCULATIONAHA.112.132159","volume":"127","author":"SP Gray","year":"2013","unstructured":"Gray, S. P.  et al. NADPH oxidase 1 plays a key role in diabetes mellitus-accelerated atherosclerosis. Circulation 127, 1888\u20131902 (2013).","journal-title":"Circulation"},{"key":"BFnrcardio20155_CR124","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s00125-013-3118-3","volume":"57","author":"E Di Marco","year":"2014","unstructured":"Di Marco, E.  et al. Pharmacological inhibition of NOX reduces atherosclerotic lesions, vascular ROS and immune-inflammatory responses in diabetic Apoe\u2212\/\u2212 mice. Diabetologia 57, 633\u2013642 (2014).","journal-title":"Diabetologia"},{"key":"BFnrcardio20155_CR125","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1161\/CIRCULATIONAHA.112.000711","volume":"127","author":"O Iida","year":"2013","unstructured":"Iida, O.  et al. Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the Sufficient Treatment of Peripheral Intervention by Cilostazol study. Circulation 127, 2307\u20132315 (2013).","journal-title":"Circulation"},{"key":"BFnrcardio20155_CR126","doi-asserted-by":"publisher","first-page":"2826","DOI":"10.1161\/CIRCULATIONAHA.104.530097","volume":"112","author":"JS Douglas Jr","year":"2005","unstructured":"Douglas, J. S. Jr  et al. Coronary stent restenosis in patients treated with cilostazol. Circulation 112, 2826\u20132832 (2005).","journal-title":"Circulation"},{"key":"BFnrcardio20155_CR127","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/0006-2952(92)90116-Z","volume":"44","author":"JE Souness","year":"1992","unstructured":"Souness, J. E., Hassall, G. A. & Parrott, D. P. Inhibition of pig aortic smooth muscle cell DNA synthesis by selective type III and type IV cyclic AMP phosphodiesterase inhibitors. Biochem. Pharmacol. 44, 857\u2013866 (1992).","journal-title":"Biochem. Pharmacol."},{"key":"BFnrcardio20155_CR128","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0021-9150(98)00147-6","volume":"142","author":"N Ishizaka","year":"1999","unstructured":"Ishizaka, N.  et al. Effects of a single local administration of cilostazol on neointimal formation in balloon-injured rat carotid artery. Atherosclerosis 142, 41\u201346 (1999).","journal-title":"Atherosclerosis"},{"key":"BFnrcardio20155_CR129","first-page":"185","volume":"57","author":"H Takase","year":"2007","unstructured":"Takase, H.  et al. Anti-atherosclerotic effect of cilostazol in apolipoprotein-E knockout mice. Arzneimittelforschung 57, 185\u2013191 (2007).","journal-title":"Arzneimittelforschung"},{"key":"BFnrcardio20155_CR130","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1164\/rccm.201301-0021PP","volume":"188","author":"B Beghe","year":"2013","unstructured":"Beghe, B., Rabe, K. F. & Fabbri, L. M. Phosphodiesterase-4 inhibitor therapy for lung diseases. Am. J. Respir. Crit. Care Med. 188, 271\u2013278 (2013).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"BFnrcardio20155_CR131","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1378\/chest.12-2332","volume":"144","author":"WB White","year":"2013","unstructured":"White, W. B.  et al. Cardiovascular safety in patients receiving roflumilast for the treatment of COPD. Chest 144, 758\u2013765 (2013).","journal-title":"Chest"},{"key":"BFnrcardio20155_CR132","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1479-5876-11-3","volume":"11","author":"CM Balarini","year":"2013","unstructured":"Balarini, C. M.  et al. Sildenafil restores endothelial function in the apolipoprotein E knockout mouse. J. Transl. Med. 11, 3 (2013).","journal-title":"J. Transl. Med."},{"key":"BFnrcardio20155_CR133","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1172\/JCI116508","volume":"91","author":"Q Xu","year":"1993","unstructured":"Xu, Q., Kleindienst, R., Waitz, W., Dietrich, H. & Wick, G. Increased expression of heat shock protein 65 coincides with a population of infiltrating T lymphocytes in atherosclerotic lesions of rabbits specifically responding to heat shock protein 65. J. Clin. Invest. 91, 2693\u20132702 (1993).","journal-title":"J. Clin. Invest."},{"key":"BFnrcardio20155_CR134","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1073\/pnas.92.3.821","volume":"92","author":"W Palinski","year":"1995","unstructured":"Palinski, W., Miller, E. & Witztum, J. L. Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc. Natl Acad. Sci. USA 92, 821\u2013825 (1995).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrcardio20155_CR135","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1161\/01.ATV.16.8.1074","volume":"16","author":"S Ameli","year":"1996","unstructured":"Ameli, S.  et al. Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits. Arterioscler. Thromb. Vasc. Biol. 16, 1074\u20131079 (1996).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"BFnrcardio20155_CR136","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S0021-9150(98)00015-X","volume":"138","author":"J George","year":"1998","unstructured":"George, J.  et al. Hyperimmunization of apo-E-deficient mice with homologous malondialdehyde low-density lipoprotein suppresses early atherogenesis. Atherosclerosis 138, 147\u2013152 (1998).","journal-title":"Atherosclerosis"},{"key":"BFnrcardio20155_CR137","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1161\/01.ATV.21.1.108","volume":"21","author":"X Zhou","year":"2001","unstructured":"Zhou, X., Caligiuri, G., Hamsten, A., Lefvert, A. K. & Hansson, G. K. LDL immunization induces T-cell-dependent antibody formation and protection against atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 21, 108\u2013114 (2001).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"BFnrcardio20155_CR138","doi-asserted-by":"publisher","first-page":"5850","DOI":"10.2174\/1381612811319330003","volume":"19","author":"DF Ketelhuth","year":"2013","unstructured":"Ketelhuth, D. F., Gistera, A., Johansson, D. K. & Hansson, G. K. T cell-based therapies for atherosclerosis. Curr. Pharm. Des. 19, 5850\u20135858 (2013).","journal-title":"Curr. Pharm. Des."},{"key":"BFnrcardio20155_CR139","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1161\/CIRCULATIONAHA.106.615609","volume":"114","author":"GH van Puijvelde","year":"2006","unstructured":"van Puijvelde, G. H.  et al. Induction of oral tolerance to oxidized low-density lipoprotein ameliorates atherosclerosis. Circulation 114, 1968\u20131976 (2006).","journal-title":"Circulation"},{"key":"BFnrcardio20155_CR140","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1161\/ATVBAHA.109.202671","volume":"30","author":"R Klingenberg","year":"2010","unstructured":"Klingenberg, R.  et al. Intranasal immunization with an apolipoprotein B-100 fusion protein induces antigen-specific regulatory T cells and reduces atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 30, 946\u2013952 (2010).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"BFnrcardio20155_CR141","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.1016\/j.jacc.2014.10.018","volume":"64","author":"PK Shah","year":"2014","unstructured":"Shah, P. K., Chyu, K., Dimayuga, P. C. & Nilsson, J. Vaccine for atherosclerosis. J. Am. Coll. Cardiol. 64, 2779\u20132791 (2014).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrcardio20155_CR142","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1161\/01.ATV.12.7.789","volume":"12","author":"Q Xu","year":"1992","unstructured":"Xu, Q.  et al. Induction of arteriosclerosis in normocholesterolemic rabbits by immunization with heat shock protein 65. Arterioscler. Thromb. 12, 789\u2013799 (1992).","journal-title":"Arterioscler. Thromb."},{"key":"BFnrcardio20155_CR143","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1161\/01.ATV.19.3.505","volume":"19","author":"J George","year":"1999","unstructured":"George, J.  et al. Enhanced fatty streak formation in C57BL\/6J mice by immunization with heat shock protein-65. Arterioscler. Thromb. Vasc. Biol. 19, 505\u2013510 (1999).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"BFnrcardio20155_CR144","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1161\/01.CIR.0000029750.99462.30","volume":"106","author":"R Maron","year":"2002","unstructured":"Maron, R.  et al. Mucosal administration of heat shock protein-65 decreases atherosclerosis and inflammation in aortic arch of low-density lipoprotein receptor-deficient mice. Circulation 106, 1708\u20131715 (2002).","journal-title":"Circulation"},{"key":"BFnrcardio20155_CR145","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1161\/CIRCULATIONAHA.107.699470","volume":"116","author":"H Ait-Oufella","year":"2007","unstructured":"Ait-Oufella, H.  et al. Measles virus nucleoprotein induces a regulatory immune response and reduces atherosclerosis in mice. Circulation 116, 1707\u20131713 (2007).","journal-title":"Circulation"},{"key":"BFnrcardio20155_CR146","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/joim.12127","volume":"275","author":"OA Ovchinnikova","year":"2014","unstructured":"Ovchinnikova, O. A.  et al. Mycobacterium bovis BCG killed by extended freeze-drying induces an immunoregulatory profile and protects against atherosclerosis. J. Intern. Med. 275, 49\u201358 (2014).","journal-title":"J. Intern. Med."}],"container-title":["Nature Reviews Cardiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrcardio.2015.5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrcardio.2015.5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrcardio.2015.5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T03:57:10Z","timestamp":1684468630000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrcardio.2015.5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,10]]},"references-count":146,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["BFnrcardio20155"],"URL":"https:\/\/doi.org\/10.1038\/nrcardio.2015.5","relation":{},"ISSN":["1759-5002","1759-5010"],"issn-type":[{"value":"1759-5002","type":"print"},{"value":"1759-5010","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,10]]},"assertion":[{"value":"10 February 2015","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}